Back to search results

Lutein, Zeaxanthin, and Fish Oil Supplementation for Cognitive Performance, Macular Degeneration, and Bone Loss

This study is looking at whether a daily supplement containing lutein, zeaxanthin, and fish oil (LZF) can improve eye health, thinking skills, and bone density in healthy adults. Researchers want to see if taking LZF for six months helps improve macular pigment optical density (MPOD), which is important for vision, as well as cognitive performance and bone mass. You might be able to join if you are between 18 and 45 years old, have a specific MPOD level (less than 0.43), and meet other health criteria. The study is currently unclear about its recruitment status.

Study design
This is a double-blind, randomized controlled trial involving 80 healthy adults. Participants will be randomly assigned to either take the LZF supplement or a placebo.
What's involved
You would take either a LZF supplement or a placebo daily for six months. This involves baseline measurements, measurements at 3 months, and a final visit at 6 months, including blood draws, MPOD tests, bone density scans (DXA), and visual cognitive performance tests.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the duration of the 6-month study, with final measurements taken at the 6-month mark.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06489873

Lutein, Zeaxathin, and Fish Oil Supplementation

Recruiting
NAAges 18–45Interventional
Texas A&M University
~80 participants
Updated 2025-09-30 on ClinicalTrials.gov
What's tested:Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)Placebo Comparator

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Macular Pigment Optical Density (MPOD)
Measured over MPOD will be measured at baseline, 3 months after the start of the study, and at the final 6 month visit, which will be the completion of the study.
+2 more outcomes measured

Conditions

Cognitive Performance
Age-Related Macular Degeneration
Bone Loss

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Karen M Beathard, PhD · PRINCIPAL_INVESTIGATOR · Texas A&M University

Who to contact

Karen M Beathard, PhD
[email protected]
979-220-2281
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.

What this trial measures

  • Macular Pigment Optical Density (MPOD)MPOD will be measured at baseline, 3 months after the start of the study, and at the final 6 month visit, which will be the completion of the study.

    The MPS II will be used to measure MPOD

  • Cognitive PerformanceCognitive performance will be measured at the three baseline appointments, the three appointments at 3 months, and the 3 appointments at 6 months after the start of the study, which will be the completion of the study

    Neurotracker 3-dimensional software will be used to measure cognitive performance. Each cognitive performance session will include 15 6-second tests that will establish a speed threshold.

  • Bone DensityBone density will be measured at baseline and at the final 6 month visit, which will be the completion of the study.

    The Horizon™ DXA System will be used for rapid, dual-energy bone density measurements in a single-sweep.